Skip to main content
OpenTrials
Completed

NCT Number: NCT03445013

A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis

The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Novella Site# 247, Boise, Idaho, United States

Loading trial locations.

About this study

This is a phase 1b, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in approximately 36 adult subjects with mild to moderate chronic plaque psoriasis. After obtaining informed consent, subjects will be randomized to active or vehicle treatment arms. Subjects will apply the study product (SB414 6% or Vehicle cream) twice daily to all affected areas of psoriasis on the trunk and/or extremities for 4 weeks.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female, 18-70 years old, and in good general health;
  • Have a clinical diagnosis of stable chronic plaque psoriasis of mild to moderate severity based on the PSGA, involving 2-15% BSA (excluding the scalp/face), present for > 6 months;
  • Must have at least 2 target plaques on trunk and/or extremities at least 5 cm2 with a TPSS > 5 and thickness sub-score > 2. Target plaques cannot be located on the groin, hands, feet, neck, face, elbows, knees, ankles or scalp;
  • Be willing to not use any other systemic agents used to treat psoriasis or apply any other topical products (medicated or over-the-counter) to the treatment sites on the trunk and/or extremities during the study;
  • Women of childbearing potential (WOCBP) must have a negative UPT prior to randomization and must agree to use an effective method of birth control during the study and for 30 days after their final study visit.

Exclusion criteria

  • Have inverse (i.e.: axillae, groin) or facial psoriasis only, erythrodermic psoriasis, guttate psoriasis, pustular psoriasis, drug-induced psoriasis, and /or psoriatic arthritis requiring treatment with disease modifying antirheumatic drugs (DMARDs);
  • Concurrent or recent use of topical or systemic medications without a sufficient washout period;
  • Are immunocompromised, including those who are known HIV positive or received immunosuppressive treatment within the past 6 months;
  • Female subjects who are pregnant, nursing mothers, or planning to become pregnant during the study.

Treatment and study plan

SB414 6%

Drug

Twice daily

Other names: NVN1000

Vehicle

Drug

Vehicle Comparator

Other names: Placebo

Primary outcomes

  1. Plasma concentrations of hMAP3

    Time frame: Day 29

    Peak plasma concentrations of hMAP3 after topical application of SB414

Secondary outcomes

  1. Safety Profile (Reported Adverse Events)

    Time frame: Day 29

    Reported Adverse Events

  2. Subject Assessment of Tolerability

    Time frame: Baseline, Week 2 and Week 4

    Subject-reported from 5-point tolerability scale overall presence and degree of itching and burning/stinging

  3. Efficacy Assessed by Target Plaque Severity Score (TPSS)

    Time frame: Baseline, Week 2 and Week 4

    Target Plaque Severity Score will be collected

  4. Pharmacodynamics of SB414

    Time frame: Day 29

    Change in relevant Pre and Post-dose tissue cytokine levels (mg/mg tissue)

  5. Efficacy Assessed by Physician's Static Global Assessment

    Time frame: Screening, Baseline, Week 2 and Week 4

    Physician's Static Global Assessment based on overall evaluation of the disease severity

  6. Efficacy as assessed by Itch Numeric Rating Scale (NRS)

    Time frame: Screening, Baseline, Week 2 and Week 4

    Itching due to psoriasis as reported by subject on a 11-point rating scale

Sponsors and collaborators

Lead sponsor

Novan, Inc.

Industry

Collaborators

  • Novella Clinical

Registry information

Official study title

A Phase 1b Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study Assessing the PK, Pharmacodynamics, Safety, and Tolerability of SB414 in Subjects With Psoriasis

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Feb 26, 2018
Registry last updated
Mar 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.